Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746976 · ClinicalTrials.gov registry record
Study of Diroximel Fumarate in the Real-World Setting
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 75
- Enrollment target
NCT04746976 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 75 participants.
The verdict
NCT04746976 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 75 participants
- Enrollment target
Study Summary
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatment; to assess long-term persistence on treatment; to assess the effect of DRF on relapses; to assess the impact of DRF on cognition; to assess the impact of DRF on participant reported outcomes (PROs) and to explore the real-world safety profile of DRF (ie, gastrointestinal \[GI\] tolerability, lymphocyte dynamics, adverse events \[AEs\] leading to discontinuation, and serious adverse events \[SAEs\]).
Interventions
- DRUG Diroximel Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2023-04-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04746976
The ClinicalTrials.gov registry entry for NCT04746976 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diroximel Fumarate is the first listed.
NCT04746976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04746976 about?
NCT04746976 is a clinical study titled "Study of Diroximel Fumarate in the Real-World Setting". The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatmen...
What is the current status of trial NCT04746976?
This trial is currently terminated. The enrollment target is 75 participants. The study started on 2021-03-01. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT04746976?
The interventions under investigation include: Diroximel Fumarate (DRUG).
Who is sponsoring clinical trial NCT04746976?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.